Drugs / BST06
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06645314 | Nov 2024 → Aug 2026 overdue | hepatocellular carcinoma | BioSyngen Pte Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BST06 | “3.0 × 10 \^ 9 BST06 cells, intravenous infusion，at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled” NCT06645314 ↗ |
| Modality | Cell therapy | “BST06 cells” NCT06645314 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06645314 ↗ |